X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse ASTRAZENECA PHARMA with ACTAVIS INC. - US - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs ACTAVIS (US) - Comparison Results

ASTRAZENECA PHARMA    Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

ACTAVIS (US)
   Change

Actavis, Inc. is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. It develops, manufactures and market generic, branded generic, legacy brands and Over... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 ASTRAZENECA PHARMA   ACTAVIS
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-18
ACTAVIS
Dec-18
ASTRAZENECA PHARMA/
ACTAVIS
5-Yr Chart
Click to enlarge
High Rs1,27813,473-   
Low Rs8839,038-   
Sales per share (Unadj.) Rs228.43,305.0-  
Earnings per share (Unadj.) Rs10.4-1,064.5-  
Cash flow per share (Unadj.) Rs16.3348.3-  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs98.813,631.7-  
Shares outstanding (eoy) m25.00332.60-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.73.4 138.9%   
Avg P/E ratio x104.2-10.6 -985.8%  
P/CF ratio (eoy) x66.432.3 205.6%  
Price / Book Value ratio x10.90.8 1,324.6%  
Dividend payout %00-   
Avg Mkt Cap Rs m27,0083,743,642 0.7%   
No. of employees `0001.416.9 8.0%   
Total wages/salary Rs m1,5350-   
Avg. sales/employee Rs Th4,210.965,044.3 6.5%   
Avg. wages/employee Rs Th1,132.20-   
Avg. net profit/employee Rs Th191.1-20,950.8 -0.9%   
INCOME DATA
Net Sales Rs m5,7101,099,249 0.5%  
Other income Rs m12321,021 0.6%   
Total revenues Rs m5,8331,120,270 0.5%   
Gross profit Rs m46328,806 1.6%  
Depreciation Rs m147469,905 0.0%   
Interest Rs m063,433 0.0%   
Profit before tax Rs m438-483,511 -0.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0123,315 0.0%   
Tax Rs m179-6,127 -2.9%   
Profit after tax Rs m259-354,069 -0.1%  
Gross profit margin %8.12.6 309.4%  
Effective tax rate %40.81.3 3,223.0%   
Net profit margin %4.5-32.2 -14.1%  
BALANCE SHEET DATA
Current assets Rs m3,209450,854 0.7%   
Current liabilities Rs m2,070398,841 0.5%   
Net working cap to sales %20.04.7 421.8%  
Current ratio x1.61.1 137.2%  
Inventory Days Days7220 369.3%  
Debtors Days Days3566 52.7%  
Net fixed assets Rs m790124,429 0.6%   
Share capital Rs m500-   
"Free" reserves Rs m2,4190-   
Net worth Rs m2,4694,533,888 0.1%   
Long term debt Rs m01,596,546 0.0%   
Total assets Rs m4,6057,087,498 0.1%  
Interest coverage xNM-6.6-  
Debt to equity ratio x00.4 0.0%  
Sales to assets ratio x1.20.2 799.4%   
Return on assets %5.6-4.1 -137.2%  
Return on equity %10.5-7.8 -134.4%  
Return on capital %17.7-4.8 -366.4%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m-1,7150-   
CASH FLOW
From Operations Rs m88392,720 0.0%  
From Investments Rs m-94215,749 -0.0%  
From Financial Activity Rs mNA-674,025 0.0%  
Net Cashflow Rs m-6-65,229 0.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ACTAVIS (US) is United States Dollars. All data has been converted at 69.63 Rs / USD

Compare ASTRAZENECA PHARMA With: ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  

Compare ASTRAZENECA PHARMA With: FULFORD INDIA  CADILA HEALTHCARE  WYETH LTD  ELDER PHARMA  JUBILANT LIFE SCIENCES  



Today's Market

Indian Indices End Flat, Crude Oil Continues Momentum, and Top Cues in Focus Today(Pre-Open)

India share markets ended marginally lower yesterday. At the closing bell yesterday, the BSE Sensex stood lower by 71 points (down 0.2%) and the NSE Nifty closed down by 24 points (down 0.2%).

Related Views On News

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 204.9% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 98 m (up 204.9% YoY). Sales on the other hand came in at Rs 2 bn (up 26.3% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Mar 29, 2019 | Updated on Mar 29, 2019

Here's an analysis of the annual report of ASTRAZENECA PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of ASTRAZENECA PHARMA. Also includes updates on the valuation of ASTRAZENECA PHARMA.

ASTRAZENECA PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 381.0% (Quarterly Result Update)

Feb 12, 2019 | Updated on Feb 12, 2019

For the quarter ended December 2018, ASTRAZENECA PHARMA has posted a net profit of Rs 291 m (up 381.0% YoY). Sales on the other hand came in at Rs 2 bn (up 67.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

7 Stocks That Will Remain Evergreen in this Era of Technological Disruption(The 5 Minute Wrapup)

Jun 13, 2019

We are living in an era of disruption. Are your stocks well equipped to adapt to changes that disruption will bring along?

Kenneth Andrade Would Like Our Real Estate Stock Recommendation with Triple Digit Upside(The 5 Minute Wrapup)

Jun 12, 2019

This real estate stock recommended in Smart Money Secrets offers the most favourable upside potential.

Why I Believe Smallcaps Will Catch up to the Sensex(Profit Hunter)

Jun 14, 2019

Smallcaps have gone nowhere even as the Sensex makes new all-time highs. Find out why Richa believes this a good opportunity to invest in smallcaps.

Why Super Investor Kenneth Andrade is Bullish on Agri Stocks...and So Are We(The 5 Minute Wrapup)

Jun 21, 2019

Andrade gives his take on agriculture, an industry from which we have already recommended two stocks.

7 Bluechips to Profit from Tech Disruption(Profit Hunter)

Jun 17, 2019

We are living in an era of disruption. Are your stocks well equipped to adapt to changes that disruption will bring along?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Jun 24, 2019 (Close)

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA - VENUS REMEDIES COMPARISON

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS